報價延遲最少15分鐘:2025/05/30 15:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.4456 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.00/-21.44
|
|
企業價值
24.14M
|
| 資產負債 |
|
每股賬面淨值
5.61
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 15:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |